Nasdaq

CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete ...

Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...
Insurancenewsnet.com

Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling

Only blood test approved by FDA as companion diagnostic for ORSERDU™ (elacestrant), Guardant360 CDx gains coverage by Aetna and Humana to identify eligible patients with advanced breast cancer prior ...
Insider Monkey

Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Caris Life Sciences, Inc. stands tenth among them. Caris Life Sciences, Inc. (NASDAQ:CAI) is a ...
Seeking Alpha

CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete ...

GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart ...